Alphamab Oncology (HKG:9966) said Chinese regulators accepted its KN035 combination therapy for review, according to a Hong Kong bourse filing Friday.
Shares of the cancer therapy developer fell over 3% in late morning trade on Monday.
The firm is seeking approval for KN035 in combination with chemotherapy drugs gemcitabine and oxaliplatin as a first-line treatment of unresectable or metastatic biliary tract cancer.
KN035 is also known as envafolimab and Enweida.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments